N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of the dietary supplement N-acetylcysteine (NAC) on
electrophysiologic (EEG) markers related to cognition, as well as performance on
psychological tests measuring cognition. The primary hypothesis is that participants treated
with NAC will show improvements in cognitive function, as measured by EEG and
performance-based tests.
Phase:
Phase 1
Details
Lead Sponsor:
VA Greater Los Angeles Healthcare System
Collaborators:
American Psychiatric Foundation VISN 22 Mental Illness Research, Education, and Clinical Center